Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 12 of 12 results for galantamine

  1. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  2. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development [GID-TA11379] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  3. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  4. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development [GID-TA11220] Expected publication date: 05 February 2025

    Technology appraisal guidance
    In development

  5. Dementia: assessment, management and support for people living with dementia and their carers (NG97)

    This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

    NICE guideline
    Published
    20 June 2018
    View recommendations

    Sections for NG97

  6. Past appeals and decisions

    July 2018 TA111 Alzheimer´s disease - donepezil, rivastigmine, galantamine and memantine (review) 13-14 August 2006 TA142 Anaemia...

  7. Research is needed on the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).

    Source guidance details Comes from guidance Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

    Research recommendation
    Published
    9 June 2015

  8. Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer's disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.

    Source guidance details Comes from guidance Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

    Research recommendation
    Published
    9 June 2015

  9. Parkinson's disease in adults (NG71)

    This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.

    NICE guideline
    Published
    19 July 2017
    View recommendations

    Sections for NG71

  10. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

    Technology appraisal guidance
    Discontinued

  11. Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)

    This guidance has been replaced by NICE technology appraisal guidance 111.

    Technology appraisal guidance
    Published
    23 January 2001

  12. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Technology appraisal guidance
    Published
    22 November 2006